Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation
Dr. Artem Cherkasov remarked, “With these newly synthesized drug candidates identified and now advancing into testing, Rakovina Therapeutics is delivering on its promise of innovation. This ...
pharmaphorum1y
Novartis expands in radio-oncology again with $1.3bn Artios alliance
The collaboration will focus on combining Artios' DNA damage response (DDR) drug candidates with ... a first-in-class DNA polymerase theta inhibitor that is about to start clinical testing.
Hosted on MSN10d
Eisbach Bio positions HRD-targeting therapy to supplant PARP inhibitors
A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP ...
eLife8d
Synergistic effect of inhibiting CHK2 and DNA replication on cancer cell growth
By inhibiting the DNA polymerases, BKC enhances the endogenous RS in cancer cells, leading to increased DNA damage. IBC specifically inhibits CHK2 to prevent DNA repair. The combined use of BKC and ...
Nature10mon
Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation
DNA strand breakage, PARP activation and a selective loss of endothelium-dependent vasodilation. Treatment with a novel potent PARP inhibitor, starting after the time of islet destruction ...
ascopubs.org23d
Next-Generation Sequencing–Guided Treatment of BRCA2-Mutant Metastatic Uterine Leiomyosarcoma With Poly(ADP-ribose) Polymerase Inhibitor Therapy
Approximately week 109; roughly 1 week before starting niraparib (poly(ADP-ribose) polymerase inhibitor). Fig 4 ... involving human subjects as defined by DHHS and US Food and Drug Administration ...